{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:55:41Z","timestamp":1769856941722,"version":"3.49.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI22C0360"],"award-info":[{"award-number":["HI22C0360"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijbiomac.2026.150083","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:03:56Z","timestamp":1767369836000},"page":"150083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Bridging discovery and therapy in precision medicine\u2014Phage display as a catalyst for nanobody innovation: A review"],"prefix":"10.1016","volume":"340","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7345-2205","authenticated-orcid":false,"given":"Hee Eon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8372-5676","authenticated-orcid":false,"given":"Jae Hyeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-3076","authenticated-orcid":false,"given":"Michael","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9119-7317","authenticated-orcid":false,"given":"Sukmook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.150083_bb0005","series-title":"Nanostructures for Drug Delivery","first-page":"807","article-title":"Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery","author":"Quinteros","year":"2017"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0010","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713229","article-title":"NANOBODY\u00ae molecule, a giga medical tool in nanodimensions","volume":"24","author":"Kunz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0030","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2486390","article-title":"Nanoscale warriors against viral invaders: a comprehensive review of nanobodies as potential antiviral therapeutics","volume":"17","author":"Verma","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0035","first-page":"501","article-title":"Nanobody-as versatile tool emerging in autoimmune diseases","volume":"5","author":"Wang","year":"2024","journal-title":"Smart Mater. Med."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0040","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1358\/dot.2019.55.6.2989843","article-title":"Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura","volume":"55","author":"Poullin","year":"2019","journal-title":"Drugs Today."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12943-025-02270-5","article-title":"Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines","volume":"24","author":"Maksymova","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.biotechadv.2010.07.004","article-title":"Phage display: concept, innovations, applications and future","volume":"28","author":"Pande","year":"2010","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0055","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3389\/fimmu.2020.01986","article-title":"Phage display derived monoclonal antibodies: from bench to bedside","volume":"11","author":"Alfaleh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0060","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.3390\/molecules28093708","article-title":"Design and construction of a synthetic nanobody library: testing its potential with a single selection round strategy","volume":"28","author":"Contreras","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0065","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1002\/bit.28816","article-title":"Advancements in nanobody generation: integrating conventional, in silico, and machine learning approaches","volume":"121","author":"Reddy","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100865","article-title":"Nanobodies: from high-throughput identification to therapeutic development","volume":"23","author":"Fridy","year":"2024","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0075","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/febs.15515","article-title":"A guide to: generation and design of nanobodies","volume":"288","author":"Muyldermans","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0080","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3390\/ijms23031482","article-title":"Easily established and multifunctional synthetic nanobody libraries as research tools","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/13102818.2021.1974943","article-title":"Nanobodies: their potential for applications in biotechnology, diagnosis and antiviral properties in Africa; focus on application in agriculture","volume":"35","author":"Njeru","year":"2021","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2022.114871","article-title":"A megadiverse na\u00efve library derived from numerous camelids for efficient and rapid development of VHH antibodies","volume":"657","author":"Wang","year":"2022","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0095","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.crvi.2014.02.004","article-title":"Construction of na\u00efve camelids VHH repertoire in phage display-based library","volume":"337","author":"Sabir","year":"2014","journal-title":"C. R. Biol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0100","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.3390\/ijms25094791","article-title":"Development, high-throughput profiling, and biopanning of a large phage display single-domain antibody library","volume":"25","author":"Lee","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0105","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3390\/molecules27072198","article-title":"Structural insights into the design of synthetic nanobody libraries","volume":"27","author":"Vald\u00e9s-Tresanco","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0110","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16228","article-title":"NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies","volume":"5","author":"Moutel","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jmb.2011.07.018","article-title":"Synthetic antibodies designed on natural sequence landscapes","volume":"412","author":"Zhai","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0120","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34317","article-title":"Synthetic single domain antibodies for the conformational trapping of membrane proteins","volume":"7","author":"Zimmermann","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0125","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0130","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0135","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/pro.3831","article-title":"Role of a noncanonical disulfide bond in the stability, affinity, and flexibility of a VHH specific for the Listeria virulence factor InlB","volume":"29","author":"Mendoza","year":"2020","journal-title":"Protein Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12967-014-0343-6","article-title":"Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications","volume":"12","author":"Yan","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2019.140321","article-title":"Unbiased libraries in protein directed evolution","volume":"1868","author":"Sayous","year":"2020","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/antib11010010","article-title":"Construction of a humanized artificial VHH library reproducing structural features of camelid VHHs for therapeutics","volume":"11","author":"Murakami","year":"2022","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/09540105.2011.606560","article-title":"Isolation and characterisation of deoxynivalenol affinity binders from a phage display library based on single-domain camelid heavy chain antibodies (VHHs)","volume":"23","author":"Tu","year":"2012","journal-title":"Food Agric. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12951-021-00768-w","article-title":"Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein","volume":"19","author":"Lu","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0165","author":"Miller"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12951-015-0091-7","article-title":"Characterization and applications of nanobodies against human procalcitonin selected from a novel naive Nanobody phage display library","volume":"13","author":"Yan","year":"2015","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111328","article-title":"Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-\u03b1-specific nanobody","volume":"137","author":"Nie","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0180","article-title":"Development of a synthetic library of humanized nanobodies for targeted IL-6 inhibition","volume":"12","author":"Wang","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028309","article-title":"Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein","volume":"6","author":"Wei","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0190","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.4161\/hv.21703","article-title":"Phage display\u2014a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications","volume":"8","author":"Bazan","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0195","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-023-37915-w","article-title":"Cryo-electron microscopy of the f1 filamentous phage reveals insights into viral infection and assembly","volume":"14","author":"Conners","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0200","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuab052","article-title":"Phage display and other peptide display technologies","volume":"46","author":"Jaroszewicz","year":"2022","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0205","article-title":"Phage-displayed synthetic library and screening platform for nanobody discovery","author":"Xia","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0210","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2213793","article-title":"Evolution of phage display libraries for therapeutic antibody discovery","volume":"15","author":"Zhang","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmb.2012.01.038","article-title":"Phagemid vectors for phage display: properties, characteristics and construction","volume":"417","author":"Qi","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0220","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1021\/bi00109a004","article-title":"Selecting high-affinity binding proteins by monovalent phage display","volume":"30","author":"Lowman","year":"1991","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150083_bb0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antib9020021","article-title":"Construction of antibody phage libraries and their application in veterinary immunovirology","volume":"9","author":"Bashir","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0230","doi-asserted-by":"crossref","first-page":"11569","DOI":"10.1021\/acsomega.9b01206","article-title":"Phage display in the quest for new selective recognition elements for biosensors","volume":"4","author":"Peltomaa","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/mps2010017","article-title":"Efficient construction and effective screening of synthetic domain antibody libraries","volume":"2","author":"Solemani Zadeh","year":"2019","journal-title":"Methods Protoc."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0240","article-title":"Construction of a T7 phage display nanobody library for bio-panning and identification of chicken dendritic cell-specific binding nanobodies","volume":"12","author":"Xu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0245","author":"Market Data Forecast"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.838082","article-title":"Research progress and applications of multivalent, multispecific and modified nanobodies for disease treatment","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0255","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/toxins11080464","article-title":"Camelid VHHs fused to human Fc fragments provide long-term protection against botulinum neurotoxin A in mice","volume":"11","author":"Godakova","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0260","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211010117","article-title":"Nanobody conjugates for targeted cancer therapy and imaging","volume":"20","author":"Kang","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0265","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.omto.2023.07.007","article-title":"Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment","volume":"30","author":"Xia","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0270","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-1759(99)00149-0","article-title":"Ribosome display: an in vitro method for selection and evolution of antibodies from libraries","volume":"231","author":"Schaffitzel","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0275","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41392-023-01686-z","article-title":"Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.697876","article-title":"Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy","volume":"11","author":"Roth","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0285","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0290","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/v13020178","article-title":"Phage display technology as a powerful platform for antibody drug discovery","volume":"13","author":"Nagano","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0295","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3389\/fimmu.2017.01746","article-title":"Nanobodies as novel agents for targeting angiogenesis in solid cancers","volume":"8","author":"Arezumand","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1012841","article-title":"Nanobodies in cell-mediated immunotherapy: on the road to fight cancer","volume":"14","author":"Maali","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0305","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","article-title":"Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy","volume":"15","author":"Babamohamadi","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0315","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: next generation of cancer diagnostics and therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0320","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2017.4","article-title":"Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade","volume":"3","author":"Zhang","year":"2017","journal-title":"Cell Discov."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0325","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3892\/ol.2023.13937","article-title":"Efficacy and safety of envafolimab in the treatment of advanced dMMR\/MSI-H solid tumors: a single-arm meta-analysis","volume":"26","author":"Fan","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0330","author":"3D Medicines (Sichuan) Co., Ltd"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0335","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/13543784.2023.2249814","article-title":"Current status and future expectations of nanobodies in oncology trials","volume":"32","author":"De Pauw","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0340","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.7150\/thno.38533","article-title":"Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies","volume":"10","author":"Schriewer","year":"2020","journal-title":"Theranostics"},{"issue":"12_Suppl","key":"10.1016\/j.ijbiomac.2026.150083_bb0345","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1158\/1538-7445.AM2022-2857","article-title":"Abstract 2857: DR30303, a SMART-VHHBody powered anti-CLDN18.2 VHH-Fc with enhanced ADCC activity for the treatment of gastric and pancreatic cancers","volume":"82","author":"Fang","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0350","article-title":"Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0355","author":"Zhejiang Doer Biologics Co., Ltd"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0360","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1177\/1535370219881129","article-title":"Structure and development of single domain antibodies as modules for therapeutics and diagnostics","volume":"244","author":"Hoey","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0365","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.csbj.2022.12.021","article-title":"Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations","volume":"21","author":"Bai","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0370","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-023-01507-4","article-title":"Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression","volume":"16","author":"Ding","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0375","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.838406","article-title":"Half-life extended nanobody-based CD38-specific bispecific killercell engagers induce killing of multiple myeloma cells","volume":"13","author":"Hambach","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.021","article-title":"Immune checkpoints in the tumor microenvironment","volume":"65","author":"Toor","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0390","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: a multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117430","article-title":"Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer","volume":"179","author":"Ni","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0400","author":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd"},{"issue":"9_Suppl","key":"10.1016\/j.ijbiomac.2026.150083_bb0405","first-page":"PS08","article-title":"Abstract PS08-06: a phase Ib\/II study to assess the safety and efficacy of PM8002 (anti-PD-L1 x VEGF-A bispecific antibody) in combination with nab-paclitaxel for first line treatment of locally advanced or metastatic triple-negative breast cancer","volume":"84","author":"Wu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0410","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antib14010016","article-title":"Immune cell engagers: advancing precision immunotherapy for cancer treatment","volume":"14","author":"In","year":"2025","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0415","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.3390\/ijms23105686","article-title":"Bispecific antibody-based immune-cell engagers and their emerging therapeutic targets in cancer immunotherapy","volume":"23","author":"Shin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.ijbiomac.2026.150083_bb0420","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1182\/blood-2022-159665","article-title":"Updated interim results from a phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC\u00ae) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Abdallah","year":"2022","journal-title":"Blood"},{"issue":"16_Suppl","key":"10.1016\/j.ijbiomac.2026.150083_bb0425","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e14511","article-title":"Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors","volume":"41","author":"Xue","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.ijbiomac.2026.150083_bb0430","article-title":"1064 mechanistic translational modeling to predict first-in-human dose for T-cell engager: HPN536 case study","volume":"12","author":"Demin","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"S2","key":"10.1016\/j.ijbiomac.2026.150083_bb0435","doi-asserted-by":"crossref","first-page":"S634","DOI":"10.1016\/j.annonc.2023.09.2185","article-title":"1046P phase I\/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: preliminary dose escalation results","volume":"34","author":"Hong","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0440","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/2326-6066.CIR-19-0837","article-title":"Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager","volume":"8","author":"Felices","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0445","author":"Masonic Cancer Center"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0450","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1007\/s00259-023-06266-5","article-title":"Albumin binding improves nanobody pharmacokinetics for dual-modality PET\/NIRF imaging of CEACAM5 in colorectal cancer models","volume":"50","author":"Song","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0455","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2018-99-113921","article-title":"Preclinical and nonclinical characterization of HPN217: a tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma","volume":"132","author":"Law","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0460","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-20-3392","article-title":"Preclinical characterization of HPN536, a trispecific, T-cell\u2013activating protein construct for the treatment of mesothelin-expressing solid tumors","volume":"27","author":"Molloy","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0465","author":"Harpoon Therapeutics, Inc"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0470","author":"Harpoon Therapeutics, Inc"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0475","author":"Sanofi"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0480","first-page":"114","article-title":"Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate","volume":"7","author":"Ma","year":"2024","journal-title":"Antib. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0485","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acscentsci.3c00288","article-title":"Covalent proteins as targeted radionuclide therapies enhance antitumor effects","volume":"9","author":"Klauser","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0490","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","article-title":"Phase I trial of 131I-GMIB-anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients","volume":"62","author":"D\u2019Huyvetter","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0495","article-title":"A phase 1, open-label, dose-escalation study of L-DOS47 in combination with pemetrexed plus carboplatin in patients with stage IV recurrent or metastatic nonsquamous NSCLC","volume":"3","author":"Piha-Paul","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0500","author":"Helix BioPharma Corporation"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0510","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0515","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40364-022-00417-w","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"10","author":"Mazinani","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0520","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/biom11020238","article-title":"The application of nanobody in CAR-T therapy","volume":"11","author":"Bao","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0530","author":"Henan Cancer Hospital"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201700095","article-title":"Bioengineering solutions for manufacturing challenges in CAR T cells","volume":"13","author":"Piscopo","year":"2018","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0540","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0545","author":"Li"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0550","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/IJN.S297631","article-title":"Nanobody: a small antibody with big implications for tumor therapeutic strategy","volume":"16","author":"Sun","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0555","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/pro.2294","article-title":"The linker between the D3 and A1 domains of vWF suppresses A1-GPIb\u03b1 catch bonds by site-specific binding to the A1 domain","volume":"22","author":"Tischer","year":"2013","journal-title":"Protein Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0560","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17474086.2020.1819230","article-title":"A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura","volume":"13","author":"G\u00f3mez-Segu\u00ed","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0565","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50545-x","article-title":"Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients","volume":"9","author":"Nurbhai","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0570","author":"VHsquared Ltd"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0575","article-title":"Nanobodies: robust miniprotein binders in biomedicine","volume":"195","author":"Kim","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0580","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-022-01821-0","article-title":"Ozoralizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0585","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0590","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13864","article-title":"A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP\/anti-IL-13 NANOBODY\u00ae compound, in healthy volunteers","volume":"17","author":"Deiteren","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0595","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","article-title":"New and emerging biological therapies for myasthenia gravis: a focussed [sic] review for clinical decision-making","volume":"39","author":"Gerischer","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0600","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240806","article-title":"Targeting TNF\/TNFR superfamilies in immune-mediated inflammatory diseases","volume":"221","author":"Veerasubramanian","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0605","article-title":"Revolutionizing antiviral therapy with nanobodies: generation and prospects","volume":"39","author":"Mustafa","year":"2023","journal-title":"Biotechnol. Rep."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0610","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.gastro.2013.06.053","article-title":"Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial","volume":"145","author":"Sarker","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0615","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2076775","article-title":"Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift","volume":"14","author":"Laroche","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0620","author":"ExeVir Bio BV"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0625","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41587-022-01249-7","article-title":"Development of spirulina for the manufacture and oral delivery of protein therapeutics","volume":"40","author":"Jester","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0630","author":"Lumen Bioscience, Inc"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0635","author":"Lumen Bioscience, Inc"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0640","article-title":"Using antibody synergy to engineer a high potency biologic cocktail against C. difficile","author":"Zhao","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0645","author":"Lumen Bioscience, Inc"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0650","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42003-022-03866-z","article-title":"Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models","volume":"5","author":"Rossotti","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0655","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2165390","article-title":"Bispecific antibody CAP256. J3LS targets V2-apex and CD4-binding sites with high breadth and potency","volume":"15","author":"Zhang","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0660","author":"National Institute of Allergy and Infectious Diseases (NIAID)"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108486","article-title":"Ocular and systemic pharmacokinetics of BI-X, a nanobody targeting VEGF and Ang-2, after intravitreal dosing in cynomolgus monkeys \u2013 evidence for half-life extension by albumin","volume":"205","author":"Fuchs","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100576","article-title":"Two phase I studies of BI 836880, a vascular endothelial growth factor\/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors","volume":"7","author":"Le Tourneau","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0675","first-page":"249","article-title":"Diabetic macular edema: upcoming therapies","volume":"263","author":"Yan","year":"2025","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0680","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s40123-024-00973-4","article-title":"Vascular endothelial growth factor C and D signaling pathways as potential targets for the treatment of neovascular age-related macular degeneration: a narrative review","volume":"13","author":"Leitch","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0685","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.3390\/ijms21175992","article-title":"The anti-ADAMTS-5 Nanobody\u00ae M6495 protects cartilage degradation ex vivo","volume":"21","author":"Siebuhr","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107623","article-title":"A new generation of nanobody research tools using improved mass spectrometry-based discovery methods","volume":"300","author":"Fridy","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0695","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm0220","article-title":"Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies","volume":"8","author":"Hanke","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0700","doi-asserted-by":"crossref","first-page":"10590","DOI":"10.3390\/cimb46090627","article-title":"Using NGS to uncover the corruption of a peptide phage display selection","volume":"46","author":"Sell","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0705","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13036-025-00513-z","article-title":"High-throughput strategies for monoclonal antibody screening: advances and challenges","volume":"19","author":"Wang","year":"2025","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0710","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/2211-5463.13850","article-title":"Nanobody engineering: computational modelling and design for biomedical and therapeutic applications","volume":"15","author":"El Salamouni","year":"2025","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0715","article-title":"The virtual lab: AI agents design new SARS-CoV-2 nanobodies with experimental validation","author":"Swanson","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0720","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/s41467-023-38063-x","article-title":"Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies","volume":"14","author":"Ruffolo","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0725","article-title":"AbNatiV: VQ-VAE-based assessment of antibody and nanobody nativeness for engineering, selection, and computational design","author":"Ramon","year":"2023","journal-title":"bioRvix"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0730","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.958584","article-title":"NanoNet: rapid and accurate end-to-end nanobody modeling by deep learning","volume":"13","author":"Cohen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0735","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/ph17040424","article-title":"Iterative in silico screening for optimizing stable conformation of anti-SARS-CoV-2 nanobodies","volume":"17","author":"Shang","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293263","article-title":"Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2","volume":"18","author":"Longsompurana","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0745","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1021\/acs.bioconjchem.2c00220","article-title":"Generation of multivalent nanobody-based proteins with improved neutralization of long \u03b1-neurotoxins from elapid snakes","volume":"33","author":"Wade","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0750","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/antib4030141","article-title":"Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended Nanobodies\u00ae","volume":"4","author":"Hoefman","year":"2015","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0755","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12951-023-02285-4","article-title":"Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice","volume":"22","author":"Abad","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0760","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/s41388-024-03066-5","article-title":"Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4","volume":"43","author":"Zeng","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0765","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/mi.2009.116","article-title":"Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis","volume":"3","author":"Vandenbroucke","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150083_bb0770","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97236-0","article-title":"Preclinical development of a bispecific TNF\u03b1\/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease","volume":"11","author":"Roberts","year":"2021","journal-title":"Sci. Rep."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T19:48:58Z","timestamp":1769802538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":154,"alternative-id":["S0141813026000097"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150083","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging discovery and therapy in precision medicine\u2014Phage display as a catalyst for nanobody innovation: A review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150083"}}